Published in Curr Oncol on October 01, 2006
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med (1996) 5.87
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol (2004) 2.97
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol (2003) 2.16
Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ (2003) 1.60
Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support. Clin Oncol (R Coll Radiol) (2004) 1.43
Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer (2000) 1.26
Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res (2000) 1.06
Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer (2004) 1.04
Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol (2001) 1.02
Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol (2004) 0.93
Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat (2005) 0.91
Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer (1993) 0.91
Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ (2005) 0.86
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer (2005) 0.82
Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be? J Clin Oncol (2005) 0.80
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol (2009) 2.71
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer (1998) 2.06
Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) (2008) 1.26
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol (2007) 1.24
Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician (2006) 1.21
Cost effective evaluation of a stability study. Can J Hosp Pharm (1987) 1.20
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol (2008) 1.20
Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat (2013) 1.17
Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat (2010) 1.12
Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. CMAJ (1989) 1.08
Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol (2012) 1.06
Inactivation of Clostridium difficile cytotoxin by the neutrophil myeloperoxidase system. J Infect Dis (1984) 1.04
Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol (2010) 0.99
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol (2009) 0.98
Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol (2012) 0.97
Prevalence of overt metastases in locally advanced breast cancer. Clin Oncol (R Coll Radiol) (2008) 0.95
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer (2010) 0.92
Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis (2009) 0.90
Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat (2013) 0.90
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Res Treat (2010) 0.90
Health care strategies to promote earlier presentation of symptomatic breast cancer: perspectives of women and family physicians. Curr Oncol (2011) 0.89
Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol (1997) 0.86
Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer--clinical examination, mammography, or magnetic resonance imaging? J Surg Oncol (2010) 0.86
Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer. Clin Exp Metastasis (2008) 0.85
Transfer of follow-up care to family physicians for early-stage breast cancer. Clin Oncol (R Coll Radiol) (2007) 0.85
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol (1999) 0.85
Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol (2010) 0.84
A primer of bone metastases management in breast cancer patients. Curr Oncol (2008) 0.84
Immune therapy for breast cancer in 2010-hype or hope? Curr Oncol (2011) 0.83
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Curr Oncol (2009) 0.83
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res Treat (2000) 0.81
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2012) 0.80
Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant (1998) 0.79
Hormonal and genetic risk factors for breast cancer. Surgeon (2003) 0.79
[Treatment of adult patients with metastatic sarcoma: current shift in concepts]. Bull Cancer (2010) 0.79
A practical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer (2005) 0.78
Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre. Curr Oncol (2013) 0.78
Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. Curr Oncol (2012) 0.78
Management of patients with Cushing's disease: a Canadian cost of illness analysis. J Popul Ther Clin Pharmacol (2014) 0.77
Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev (2005) 0.77
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. Clin Exp Metastasis (2009) 0.77
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer. J Clin Pathol (2009) 0.76
Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy? Clin Oncol (R Coll Radiol) (2012) 0.76
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? Ann Surg Oncol (2014) 0.76
Dual blockade of HER2 - twice as good or twice as toxic? Clin Oncol (R Coll Radiol) (2012) 0.76
Breast cancer in pregnancy: are taxanes safe? Clin Oncol (R Coll Radiol) (2006) 0.76
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Res Treat (2013) 0.75
Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma. Curr Oncol (2012) 0.75
Sexuality in women receiving chemotherapy for breast cancer. Ann Oncol (1997) 0.75
Sternal resection for recurrent breast cancer: a cautionary tale. Curr Oncol (2008) 0.75
Caught in the middle: case study of a brachial (sentry) lymph node recurrence after resection and locoregional breast radiotherapy. Curr Oncol (2012) 0.75
Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer? Minerva Chir (2015) 0.75
Cancer-associated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis. Int J Oral Maxillofac Surg (2011) 0.75
Using filgrastim efficiently. Pharmacoeconomics (1996) 0.75
The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat (2006) 0.75
A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care (1998) 0.75
Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations. Melanoma Res (1995) 0.75
Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Ann Oncol (1997) 0.75
Misoprostol-associated platelet aggregation dysfunction and increased gastrointestinal blood loss. Eur J Gastroenterol Hepatol (1997) 0.75